Glioma–Immune crosstalk in the tumor microenvironment: mechanistic insights and therapeutic translation
Medical Oncology · 12.03.2026 · 43 (4)
DOI: 10.1007/s12032-026-03239-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, online erschienen am 12.03.2026. Verfasst von Saba Yousaf und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Enzyme Biotechnology Laboratory, University of Agriculture, Faisalabad, 38000, Pakistan. Hauptthemen laut MEDLINE: Tumor Microenvironment, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben.
Abstract (Originalsprache)
Tumor progression is governed not only by genetic alterations but also by the dynamic interplay within the tumor microenvironment (TME). In gliomas, this microenvironment is shaped by diverse immune populations, including regulatory T cells and tumor-associated macrophages (TAMs), which influence tumor growth through direct interactions and cytokine signaling. A central challenge in glioma therapy is predicting patient response to immunotherapy, as both glioma cells and the TME evolve from diagnosis to recurrence. Advances in spatial transcriptomics and proteomics reveal that gliomas are composed of distinct molecular regions with unique lineage markers and biological behaviors. This heterogeneity underscores the limitations of single biopsies and highlights the need for multi-regional and longitudinal sampling. Serial biopsies and resections are therefore essential to capture tumor evolution and guide personalized immunotherapy. Standard glioblastoma (GBM) treatments, including radiation and temozolomide, also reshape immune cell dynamics, yet their contributions to therapy resistance remain incompletely understood. Clarifying these effects may inform more effective combination strategies. While TAMs dominate current research due to their prevalence in the glioma milieu, expanding focus to other immune cell subsets is critical for a more complete understanding of tumor-immune interactions. This review explores how radiotherapy, chemotherapy, and emerging immunotherapies reprogram the glioma TME by altering immune cell infiltration, cytokine networks, and stromal interactions. A deeper understanding of these processes will be vital for developing personalized and durable therapeutic approaches for glioma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry, Enzyme Biotechnology Laboratory, University of Agriculture, Faisalabad, 38000, Pakistan.
- Department of Biochemistry, Bahauddin Zakariya University, Multan, 60800, Pakistan. sibtain@bzu.edu.pk.
- Biochemistry Section, University of Veterinary and Animal Sciences, Jhang Campus, Lahore, Pakistan. muhammad.arshad@uvas.edu.pk.
- Medical and Biological Physics Department, Azerbaijan Medical University, P.O. Box 9004, Baku, Azerbaijan.
- Department of Biochemistry, Riphah International University, Faisalabad, 38000, Pakistan.
- Research Center for Advanced Materials Science (RCAMS), King Khalid University, P.O. Box 9004, Abha, 61413, Saudi Arabia.
Zitieren
APA
Yousaf, S., Ahmed, S., Arshad, M., Mammadova, K., Khokhar, A. M., Fawy, K. F., & Rafeeq, H. (2026). Glioma–Immune crosstalk in the tumor microenvironment: mechanistic insights and therapeutic translation. Medical Oncology, 43(4). https://doi.org/10.1007/s12032-026-03239-0
Vancouver
Yousaf S, Ahmed S, Arshad M, Mammadova K, Khokhar AM, Fawy KF, et al. Glioma–Immune crosstalk in the tumor microenvironment: mechanistic insights and therapeutic translation. Medical Oncology. 2026;43(4). doi:10.1007/s12032-026-03239-0
BibTeX
@article{Yousaf2026,
author = {Yousaf, Saba and Ahmed, Sibtain and Arshad, Muhammad and Mammadova, Khayala and Khokhar, Abdul Maajid and Fawy, Khaled Fahmi and Rafeeq, Hamza},
title = {Glioma–Immune crosstalk in the tumor microenvironment: mechanistic insights and therapeutic translation},
journal = {Medical Oncology},
year = {2026},
volume = {43},
number = {4},
doi = {10.1007/s12032-026-03239-0}
}
EUVIMED